Liletta from Actavis, Medicines360 now available in the U.S.
DUBLIN and SAN FRANCISCO — Actavis and Medicines360, a nonprofit women’s health pharmaceutical company, on Monday announced that Liletta (levonorgestrel-releasing intrauterine system) in 52 mg is now available in the United States. Liletta is used by women to prevent pregnancy for up to three years, according to the companies.
Liletta was granted Food and Drug Administration approval in February. It’s placed in the uterus by a healthcare professional and provides a continuous release of levonorgestrel to prevent pregnancy, the companies stated.
"The availability of Liletta marks another significant achievement in women's health," said Carolyn Westhoff, MD, M.Sc, professor, division director, Family Planning and Preventive Services, Columbia University Medical Center. "It's critical that women have choices when it comes to their preferred contraception and I am pleased that I can offer my appropriate patients this new safe and effective option."
Liletta is now commercially available in doctor’s offices. Through the Actavis-Medicine360 partnership, it’s priced lower for public health clinics enrolled in the 340B Drug Pricing Program.
"The commercial availability of Liletta represents a remarkable next step for women's health in the U.S., providing IUD-appropriate women, regardless of income and insurance coverage, with a safe and effective contraceptive option," said Pamela Weir, COO of Medicines360. "Through this truly innovative partnership, women will now have an accessible, affordable option for effective, long-term contraception."